Author:
Laurie Matthew T.,White Corin V.,Retallack Hanna,Wu Wesley,Moser Matthew S.,Sakanari Judy,Ang Kenny,Wilson Christopher,Arkin Michelle R.,DeRisi Joseph L.
Abstract
AbstractBalamuthia mandrillarisis a pathogenic free-living amoeba that causes a rare but almost always fatal infection of the central nervous system called granulomatous amoebic encephalitis (GAE). Two distinct forms ofB. mandrillaris– a proliferative trophozoite form and a non-proliferative cyst form, which is highly resistant to harsh physical and chemical conditions – have been isolated from environmental samples worldwide and are both observed in infected tissue. Patients suffering from GAE are typically treated with aggressive and prolonged multi-drug regimens often including the antimicrobial agents miltefosine and pentamidine isethionate. However, survival rates remain low and studies evaluating the susceptibility ofB. mandrillaristo these compounds and other potential therapeutics are limited. To address the need for more effective treatments, we screened 2,177 clinically-approved compounds forin vitroactivity againstB. mandrillaris. The quinoline antibiotic nitroxoline, which has safely been used in humans to treat urinary tract infections, was identified as a lead compound. We show that nitroxoline inhibits both trophozoites and cysts at low micromolar concentrations, which are within a physiologically relevant range. We compare thein vitroefficacy of nitroxoline to drugs currently used in the standard of care for GAE and find that nitroxoline is the most potent and selective inhibitor ofB. mandrillaristested. Furthermore, we demonstrate that nitroxoline preventsB. mandrillaris-mediateddestruction of host cells in cultured fibroblast and primary brain explant models also at physiologically relevant concentrations. Together, our findings indicate that nitroxoline is a promising candidate for repurposing as a novel treatment ofB. mandrillarisinfections.ImportanceBalamuthia mandrillarisis responsible for hundreds of reported cases of amoebic encephalitis, the majority of which have been fatal. Despite being an exceptionally deadly pathogen,B. mandrillarisis understudied, leaving many open questions regarding epidemiology, diagnosis, and treatment. Due to the lack of effective drugs to fightB. mandrillarisinfections, mortality rates remain high even for patients receiving intensive care. This study addresses the need for new anti-amoebic drugs using a high-throughput screening approach to identify novelB. mandrillarisinhibitors. The most promising candidate identified was the quinoline antibiotic nitroxoline, which has a long history of safe use in humans. We show that nitroxoline killsB. mandrillarisat physiologically relevant concentrations and exhibits greater potency and selectivity than drugs commonly used in the current standard of care. The findings we present demonstrate the potential of nitroxoline to be an important new tool in the treatment of life threateningB. mandrillarisinfections.
Publisher
Cold Spring Harbor Laboratory
Reference74 articles.
1. Under the Radar:BalamuthiaAmebic Encephalitis
2. Pathogenic and opportunistic free-living amoebae:Acanthamoebaspp.,Balamuthia mandrillaris,Naegleria fowleri, andSappinia diploidea
3. Visvesvara GS. 2011. Pathogenic and Opportunistic Free-Living AmebaeManual of Clinical Microbiology, 10th Edition. American Society of Microbiology.
4. Balamuthia mandrillaris infection of the skin and central nervous system: an emerging disease of concern to many specialties in medicine
5. Lehmer LM , Ulibarri GE , Ragsdale BD , Kunkle J. 2017. Cutaneous Balamuthia mandrillaris infection as a precursor to Balamuthia amoebic encephalitis (BAE) in a healthy 84-year-old Californian. Dermatol Online J 23.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献